Skip to main content
Top
Published in: Journal of General Internal Medicine 6/2019

01-06-2019 | Original Research

Behavioral Economics Interventions to Improve Outpatient Antibiotic Prescribing for Acute Respiratory Infections: a Cost-Effectiveness Analysis

Authors: Cynthia L. Gong, Pharm.D., Kenneth M. Zangwill, M.D., Joel W. Hay, Ph.D., Daniella Meeker, Ph.D., Jason N. Doctor, Ph.D.

Published in: Journal of General Internal Medicine | Issue 6/2019

Login to get access

ABSTRACT

Background

Behavioral economics interventions have been shown to effectively reduce the rates of inappropriate antibiotic prescriptions for acute respiratory infections (ARIs).

Objective

To determine the cost-effectiveness of three behavioral economic interventions designed to reduce inappropriate antibiotic prescriptions for ARIs.

Design

Thirty-year Markov model from the US societal perspective with inputs derived from the literature and CDC surveillance data.

Subjects

Forty-five-year-old adults with signs and symptoms of ARI presenting to a healthcare provider.

Interventions

(1) Provider education on guidelines for the appropriate treatment of ARIs; (2) Suggested Alternatives, which utilizes computerized clinical decision support to suggest non-antibiotic treatment choices in lieu of antibiotics; (3) Accountable Justification, which mandates free-text justification into the patient’s electronic health record when antibiotics are prescribed; and (4) Peer Comparison, which sends a periodic email to prescribers about his/her rate of inappropriate antibiotic prescribing relative to clinician colleagues.

Main Measures

Discounted costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios.

Key Results

Each intervention has lower costs but higher QALYs compared to provider education. Total costs for each intervention were $178.21, $173.22, $172.82, and $172.52, and total QALYs were 14.68, 14.73, 14.74, and 14.74 for the control, Suggested Alternatives, Accountable Justification, and Peer Comparison groups, respectively. Results were most sensitive to the quality-of-life of the uninfected state, and the likelihood and costs for antibiotic-associated adverse events.

Conclusions

Behavioral economics interventions can be cost-effective strategies for reducing inappropriate antibiotic prescriptions by reducing healthcare resource utilization.
Literature
1.
go back to reference Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 2008;47(6):735–43.CrossRefPubMed Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 2008;47(6):735–43.CrossRefPubMed
2.
go back to reference Llop CJ, Tuttle E, Tillotson GS, LaPlante K, File TM, Jr. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study. Hosp Pract (1995). 2017;1–8. Llop CJ, Tuttle E, Tillotson GS, LaPlante K, File TM, Jr. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study. Hosp Pract (1995). 2017;1–8.
3.
go back to reference Jones SC, Budnitz DS, Sorbello A, Mehta H. US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions. Pharmacoepidemiol Drug Saf 2013;22(10):1099–106.PubMedPubMedCentral Jones SC, Budnitz DS, Sorbello A, Mehta H. US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions. Pharmacoepidemiol Drug Saf 2013;22(10):1099–106.PubMedPubMedCentral
4.
go back to reference Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 2007;29(6):630–6.CrossRefPubMed Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 2007;29(6):630–6.CrossRefPubMed
5.
go back to reference Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature 2016;529(7586):336–43.CrossRefPubMed Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature 2016;529(7586):336–43.CrossRefPubMed
6.
go back to reference CDC. Antibiotic resistance threats. Atlanta, GA: US Department of Health and Human Services; 2013. CDC. Antibiotic resistance threats. Atlanta, GA: US Department of Health and Human Services; 2013.
7.
go back to reference CDC. About Antimicrobial Resistance: Four Core Actions to Fight Resistance. Centers for Disease Control and Prevention; 2015. CDC. About Antimicrobial Resistance: Four Core Actions to Fight Resistance. Centers for Disease Control and Prevention; 2015.
8.
go back to reference Ranji SR, Steinman MAS, Kaveh G, Sundaram V, Lewis R, Arnold S, et al. Antibiotic Prescribing Behavior Vol. 4: Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies. Technical Review 9 (Prepared by Stanford University-UCSF Evidence-based Practice Center under Contract No. 290–02-0017. Rockville, MD: Agency for Healthcare Research and Quality; 2006. Ranji SR, Steinman MAS, Kaveh G, Sundaram V, Lewis R, Arnold S, et al. Antibiotic Prescribing Behavior Vol. 4: Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies. Technical Review 9 (Prepared by Stanford University-UCSF Evidence-based Practice Center under Contract No. 290–02-0017. Rockville, MD: Agency for Healthcare Research and Quality; 2006.
9.
go back to reference Drekonja D, Filice G, Greer N, Olson A, MacDonald R, Rutks I, et al. Antimicrobial Stewardship Programs in Outpatient Settings: A Systematic Review. Washington (DC); 2014. Drekonja D, Filice G, Greer N, Olson A, MacDonald R, Rutks I, et al. Antimicrobial Stewardship Programs in Outpatient Settings: A Systematic Review. Washington (DC); 2014.
10.
go back to reference Loewenstein G, Brennan T, Volpp KG. Asymmetric paternalism to improve health behaviors. JAMA 2007;298(20):2415–7.CrossRefPubMed Loewenstein G, Brennan T, Volpp KG. Asymmetric paternalism to improve health behaviors. JAMA 2007;298(20):2415–7.CrossRefPubMed
11.
go back to reference Frolich A, Talavera JA, Broadhead P, Dudley RA. A behavioral model of clinician responses to incentives to improve quality. Health Policy 2007;80(1):179–93.CrossRefPubMed Frolich A, Talavera JA, Broadhead P, Dudley RA. A behavioral model of clinician responses to incentives to improve quality. Health Policy 2007;80(1):179–93.CrossRefPubMed
12.
go back to reference Meeker D, Linder JA, Fox CR, Friedberg MW, Persell SD, Goldstein NJ, et al. Effect of Behavioral Interventions on Inappropriate Antibiotic Prescribing Among Primary Care Practices: A Randomized Clinical Trial. JAMA 2016;315(6):562–70.CrossRefPubMedPubMedCentral Meeker D, Linder JA, Fox CR, Friedberg MW, Persell SD, Goldstein NJ, et al. Effect of Behavioral Interventions on Inappropriate Antibiotic Prescribing Among Primary Care Practices: A Randomized Clinical Trial. JAMA 2016;315(6):562–70.CrossRefPubMedPubMedCentral
13.
go back to reference Hallsworth M, Chadborn T, Sallis A, Sanders M, Berry D, Greaves F, et al. Provision of social norm feedback to high prescribers of antibiotics in general practice: a pragmatic national randomised controlled trial. Lancet 2016;387(10029):1743–52.CrossRefPubMedPubMedCentral Hallsworth M, Chadborn T, Sallis A, Sanders M, Berry D, Greaves F, et al. Provision of social norm feedback to high prescribers of antibiotics in general practice: a pragmatic national randomised controlled trial. Lancet 2016;387(10029):1743–52.CrossRefPubMedPubMedCentral
14.
go back to reference Hunter R. Cost-effectiveness of point-of-care C-reactive protein tests for respiratory tract infection in primary care in England. Adv Ther 2015;32(1):69–85.CrossRefPubMedPubMedCentral Hunter R. Cost-effectiveness of point-of-care C-reactive protein tests for respiratory tract infection in primary care in England. Adv Ther 2015;32(1):69–85.CrossRefPubMedPubMedCentral
15.
go back to reference Michaelidis CI, Zimmerman RK, Nowalk MP, Fine MJ, Smith KJ. Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults. J Gen Intern Med 2014;29(4):579–86.CrossRefPubMed Michaelidis CI, Zimmerman RK, Nowalk MP, Fine MJ, Smith KJ. Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults. J Gen Intern Med 2014;29(4):579–86.CrossRefPubMed
16.
go back to reference Oppong R, Jit M, Smith RD, Butler CC, Melbye H, Molstad S, et al. Cost-effectiveness of point-of-care C-reactive protein testing to inform antibiotic prescribing decisions. Br J Gen Pract 2013;63(612):e465–71.CrossRefPubMedPubMedCentral Oppong R, Jit M, Smith RD, Butler CC, Melbye H, Molstad S, et al. Cost-effectiveness of point-of-care C-reactive protein testing to inform antibiotic prescribing decisions. Br J Gen Pract 2013;63(612):e465–71.CrossRefPubMedPubMedCentral
17.
go back to reference Zoorob R, Sidani MA, Fremont RD, Kihlberg C. Antibiotic Use in Acute Upper Respiratory Tract Infections. Am Fam Physician . 2012 86(9):817–22.PubMed Zoorob R, Sidani MA, Fremont RD, Kihlberg C. Antibiotic Use in Acute Upper Respiratory Tract Infections. Am Fam Physician . 2012 86(9):817–22.PubMed
18.
go back to reference Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob 2008;7:1.CrossRefPubMedPubMedCentral Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob 2008;7:1.CrossRefPubMedPubMedCentral
19.
go back to reference Spedicato GA, Kang TS, Yalamanchi SB, Yadav D. markovchain. 0.6.6 ed: R; 2017. Spedicato GA, Kang TS, Yalamanchi SB, Yadav D. markovchain. 0.6.6 ed: R; 2017.
20.
21.
go back to reference Sokol W. Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 respiratory surveillance program. Am J Med 2001;111 Suppl 9A:19S–24S.CrossRefPubMed Sokol W. Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 respiratory surveillance program. Am J Med 2001;111 Suppl 9A:19S–24S.CrossRefPubMed
22.
go back to reference Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012;54(8):e72-e112.CrossRefPubMed Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012;54(8):e72-e112.CrossRefPubMed
23.
go back to reference Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis 2012;55(10):e86–102.CrossRefPubMed Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis 2012;55(10):e86–102.CrossRefPubMed
24.
go back to reference Fleming-Dutra KE, Hersh AL, Shapiro DJ, Bartoces M, Enns EA, File TM, Jr., et al. Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011. JAMA 2016;315(17):1864–73. Fleming-Dutra KE, Hersh AL, Shapiro DJ, Bartoces M, Enns EA, File TM, Jr., et al. Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011. JAMA 2016;315(17):1864–73.
25.
go back to reference Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2014. In: Prevention. CfDCa, ed. Centers for Disease Control and Prevention; 2014. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2014. In: Prevention. CfDCa, ed. Centers for Disease Control and Prevention; 2014.
26.
go back to reference Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. J Allergy Clin Immunol 2014;133(4):1075–83.CrossRefPubMed Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. J Allergy Clin Immunol 2014;133(4):1075–83.CrossRefPubMed
27.
go back to reference AHRQ. National Statistics on All Stays. Healthcare Cost and Utilization Project (HCUP): Agency for Healthcare Research and Quality; 2016. AHRQ. National Statistics on All Stays. Healthcare Cost and Utilization Project (HCUP): Agency for Healthcare Research and Quality; 2016.
29.
go back to reference Fokkens WJ, Hoffmans R, Thomas M. Avoid prescribing antibiotics in acute rhinosinusitis. BMJ 2014;349:g5703.CrossRefPubMed Fokkens WJ, Hoffmans R, Thomas M. Avoid prescribing antibiotics in acute rhinosinusitis. BMJ 2014;349:g5703.CrossRefPubMed
30.
go back to reference Little P, Stuart B, Hobbs FD, Butler CC, Hay AD, Campbell J, et al. Predictors of suppurative complications for acute sore throat in primary care: prospective clinical cohort study. BMJ 2013;347:f6867.CrossRefPubMedPubMedCentral Little P, Stuart B, Hobbs FD, Butler CC, Hay AD, Campbell J, et al. Predictors of suppurative complications for acute sore throat in primary care: prospective clinical cohort study. BMJ 2013;347:f6867.CrossRefPubMedPubMedCentral
31.
go back to reference Centers for Disease Control and Prevention. BRFSS Prevalence & Trends Data. National Center for Chronic Disease Prevention and Health Promotion; 2015. Centers for Disease Control and Prevention. BRFSS Prevalence & Trends Data. National Center for Chronic Disease Prevention and Health Promotion; 2015.
32.
go back to reference Zhang S, Palazuelos-Munoz S, Balsells EM, Nair H, Chit A, Kyaw MH. Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC Infect Dis 2016;16(1):447.CrossRefPubMedPubMedCentral Zhang S, Palazuelos-Munoz S, Balsells EM, Nair H, Chit A, Kyaw MH. Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC Infect Dis 2016;16(1):447.CrossRefPubMedPubMedCentral
33.
go back to reference Luo N, Johnson JA, Shaw JW, Feeny D, Coons SJ. Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Med Care 2005;43(11):1078–86.CrossRefPubMed Luo N, Johnson JA, Shaw JW, Feeny D, Coons SJ. Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Med Care 2005;43(11):1078–86.CrossRefPubMed
34.
go back to reference Bergus GR, Weber CA, Ernst ME, Ernst EJ. Do antibiotics affect the quality of life of patients with upper respiratory tract illnesses? It might depend on one’s luck. Int J Clin Pract 2008;62(6):855–9.CrossRefPubMed Bergus GR, Weber CA, Ernst ME, Ernst EJ. Do antibiotics affect the quality of life of patients with upper respiratory tract illnesses? It might depend on one’s luck. Int J Clin Pract 2008;62(6):855–9.CrossRefPubMed
35.
go back to reference Johnson FR, Banzhaf MR, Desvousges WH. Willingness to pay for improved respiratory and cardiovascular health: a multiple-format, stated-preference approach. Health Econ 2000;9(4):295–317.CrossRefPubMed Johnson FR, Banzhaf MR, Desvousges WH. Willingness to pay for improved respiratory and cardiovascular health: a multiple-format, stated-preference approach. Health Econ 2000;9(4):295–317.CrossRefPubMed
36.
go back to reference Shupo F, Dorey J, Aballea S, McGarry T, Odeyemi II, Toumi M. PIN75 Health-Related Quality of Life of Clostridium Difficile Infection: A Methodological Contribution to Direct Utility Elicitation by TTO. Value Health 2012;15(7):A399.CrossRef Shupo F, Dorey J, Aballea S, McGarry T, Odeyemi II, Toumi M. PIN75 Health-Related Quality of Life of Clostridium Difficile Infection: A Methodological Contribution to Direct Utility Elicitation by TTO. Value Health 2012;15(7):A399.CrossRef
37.
go back to reference Egger ME, Myers JA, Arnold FW, Pass LA, Ramirez JA, Brock GN. Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for Community-Aquired Pneumonia. BMC Med Inform Decis Mak 2016;16:34.CrossRefPubMedPubMedCentral Egger ME, Myers JA, Arnold FW, Pass LA, Ramirez JA, Brock GN. Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for Community-Aquired Pneumonia. BMC Med Inform Decis Mak 2016;16:34.CrossRefPubMedPubMedCentral
38.
go back to reference Fendrick AM, Monto AS, Nightengale B. The Economic Burden of Non–Influenza-Related Viral Respiratory Tract Infection in the United States. Arch Intern Med 2003;163(4):487–94.CrossRefPubMed Fendrick AM, Monto AS, Nightengale B. The Economic Burden of Non–Influenza-Related Viral Respiratory Tract Infection in the United States. Arch Intern Med 2003;163(4):487–94.CrossRefPubMed
39.
go back to reference Administration SS. Period Life Table, 2013. In: Administration SS, ed. Actuarial Life Table: Social Security Administration; 2016. Administration SS. Period Life Table, 2013. In: Administration SS, ed. Actuarial Life Table: Social Security Administration; 2016.
40.
go back to reference Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-Effectiveness in Health and Medicine: 2nd Edition. New York: Oxford University Press; 2016.CrossRef Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-Effectiveness in Health and Medicine: 2nd Edition. New York: Oxford University Press; 2016.CrossRef
41.
go back to reference Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Mak 1998;18(2 Suppl):S68–80.CrossRef Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Mak 1998;18(2 Suppl):S68–80.CrossRef
42.
go back to reference Using Behavioral Science Insights to Better Serve the American People. Online: The White House Office of the Press Secretary; 2015. Using Behavioral Science Insights to Better Serve the American People. Online: The White House Office of the Press Secretary; 2015.
43.
go back to reference Bassi J, Lau F. Measuring value for money: a scoping review on economic evaluation of health information systems. J Am Med Inform Assoc 2013;20(4):792–801.CrossRefPubMedPubMedCentral Bassi J, Lau F. Measuring value for money: a scoping review on economic evaluation of health information systems. J Am Med Inform Assoc 2013;20(4):792–801.CrossRefPubMedPubMedCentral
44.
go back to reference O'Reilly D, Tarride JE, Goeree R, Lokker C, McKibbon KA. The economics of health information technology in medication management: a systematic review of economic evaluations. J Am Med Inform Assoc 2012;19(3):423–38.CrossRefPubMed O'Reilly D, Tarride JE, Goeree R, Lokker C, McKibbon KA. The economics of health information technology in medication management: a systematic review of economic evaluations. J Am Med Inform Assoc 2012;19(3):423–38.CrossRefPubMed
45.
go back to reference Antibiotic Use in Food-Producing Animals. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS). Antibiotic Use in Food-Producing Animals. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS).
46.
go back to reference Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010;8(4):260–71.CrossRefPubMed Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010;8(4):260–71.CrossRefPubMed
47.
go back to reference Andersson DI, Hughes D. Persistence of antibiotic resistance in bacterial populations. FEMS Microbiol Rev 2011;35(5):901–11.CrossRefPubMed Andersson DI, Hughes D. Persistence of antibiotic resistance in bacterial populations. FEMS Microbiol Rev 2011;35(5):901–11.CrossRefPubMed
48.
go back to reference Belongia EA, Sullivan BJ, Chyou PH, Madagame E, Reed KD, Schwartz B. A Community Intervention Trial to Promote Judicious Antibiotic Use and Reduce Penicillin-Resistant Streptococcus pneumoniae Carriage in Children. Pediatrics 2001;108(3):575–83.CrossRefPubMed Belongia EA, Sullivan BJ, Chyou PH, Madagame E, Reed KD, Schwartz B. A Community Intervention Trial to Promote Judicious Antibiotic Use and Reduce Penicillin-Resistant Streptococcus pneumoniae Carriage in Children. Pediatrics 2001;108(3):575–83.CrossRefPubMed
49.
go back to reference Hennessy TW, Petersen KM, Bruden D, Parkinson AJ, Hurlburt D, Getty M, et al. Changes in antibiotic-prescribing practices and carriage of penicillin-resistant Streptococcus pneumoniae: A controlled intervention trial in rural Alaska. Clin Infect Dis 2002;34(12):1543–50.CrossRefPubMed Hennessy TW, Petersen KM, Bruden D, Parkinson AJ, Hurlburt D, Getty M, et al. Changes in antibiotic-prescribing practices and carriage of penicillin-resistant Streptococcus pneumoniae: A controlled intervention trial in rural Alaska. Clin Infect Dis 2002;34(12):1543–50.CrossRefPubMed
50.
go back to reference Electronic Health Record (EHR) Adoption. In: Technology TOotNCfHI, ed. Health Information Technology Data Summaries. The Office of the National Coordinator for Health Information Technology; 2015. Electronic Health Record (EHR) Adoption. In: Technology TOotNCfHI, ed. Health Information Technology Data Summaries. The Office of the National Coordinator for Health Information Technology; 2015.
51.
go back to reference Gilmer TP, O'Connor PJ, Sperl-Hillen JM, Rush WA, Johnson PE, Amundson GH, et al. Cost-effectiveness of an electronic medical record based clinical decision support system. Health Serv Res 2012;47(6):2137–58.CrossRefPubMedPubMedCentral Gilmer TP, O'Connor PJ, Sperl-Hillen JM, Rush WA, Johnson PE, Amundson GH, et al. Cost-effectiveness of an electronic medical record based clinical decision support system. Health Serv Res 2012;47(6):2137–58.CrossRefPubMedPubMedCentral
52.
go back to reference Shekelle P, Morton SC, Keeler EB. Costs and Benefits of Health Information Technology. Evidence Report/Technology Assessment No. 132. (Prepared by the Southern California Evidence-based Practice Center under Contract No. 290–02-0003.) AHRQ Publication No. 06-E006. Rockville, MD: Agency for Healthcare Research and Quality; 2006. Shekelle P, Morton SC, Keeler EB. Costs and Benefits of Health Information Technology. Evidence Report/Technology Assessment No. 132. (Prepared by the Southern California Evidence-based Practice Center under Contract No. 290–02-0003.) AHRQ Publication No. 06-E006. Rockville, MD: Agency for Healthcare Research and Quality; 2006.
Metadata
Title
Behavioral Economics Interventions to Improve Outpatient Antibiotic Prescribing for Acute Respiratory Infections: a Cost-Effectiveness Analysis
Authors
Cynthia L. Gong, Pharm.D.
Kenneth M. Zangwill, M.D.
Joel W. Hay, Ph.D.
Daniella Meeker, Ph.D.
Jason N. Doctor, Ph.D.
Publication date
01-06-2019
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 6/2019
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-018-4467-x

Other articles of this Issue 6/2019

Journal of General Internal Medicine 6/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.